RLS-0071

Phase 2Small molecule

RLS-0071 is one of 72 small molecule programs targeting Steroid-Refractory Acute Graft-Versus-Host Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Steroid-Refractory Acute Graft-Versus-Host DiseaseRecruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

EncephalopathyRecruiting

Steroid-Refractory Acute Graft-Versus-Host DiseasePhase 2

Recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

EncephalopathyPhase 2

Recruiting

Competition

Competitive Landscape

120 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

EXDENSUR

GGlaxo Dba Glaxosmithkline

Phase 3

2 2

Lunsekimig

Sanofi

Phase 3

3 3

Tozorakimab

AstraZeneca

Phase 3

2 4

CM310

KKeymed Biosciences Co.Ltd

Phase 3

1 5

Sildenafil ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

2 6

Astegolimab

Roche

Phase 3

3 7

Titrated Oxygen

RRigshospitalet, Denmark

Phase 3

1 8

RLS-0071

RReAlta Life Sciences, Inc.

Phase 2

1 9

Calciferol

Duragesic

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Steroid-Refractory Acute Graft-Versus-Host Disease

NCT06343792

Clinical

Trials by Indication[1]

Encephalopathy1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

Recruiting·RReAlta Life Sciences, Inc.·Phase 2·NCT05778188·42 enrolled

Adult1 trial

A Clinical Study to Determine the Safety, Tolerability and Effect of RLS-0071 Doses When Given to Healthy Adults After Inhaling LPS

Completed·RReAlta Life Sciences, Inc.·Phase 1·NCT05351671·30 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Active, not recruiting·RReAlta Life Sciences, Inc.·Phase 2·NCT06175065·24 enrolled

COVID-191 trial

A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program

Completed·RReAlta Life Sciences, Inc.·Phase 1·NCT05298787·56 enrolled

Steroid-Refractory Acute Graft-Versus-Host Disease1 trial

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

Recruiting·RReAlta Life Sciences, Inc.·Phase 2·NCT06343792·66 enrolled

1 more indication

Respiratory Failure1 trial

A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

Withdrawn·RReAlta Life Sciences, Inc.·Phase 1·NCT04574869

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for RLS-0071. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RLS-0071 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RLS-0071. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ReAlta Life Sciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RReAlta Life Sciences, Inc.

RLS-0071

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Encephalopathy1 trial

Adult1 trial

Chronic Obstructive Pulmonary Disease1 trial

COVID-191 trial

Steroid-Refractory Acute Graft-Versus-Host Disease1 trial

Respiratory Failure1 trial

References

Drug Info

Quick Facts

Related News